• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Very long-term outcomes of pediatric patients treated for optic pathway gliomas: A longitudinal cohort study.儿童视神经胶质瘤治疗后非常长期的结果:一项纵向队列研究。
Neuro Oncol. 2024 Jul 5;26(7):1310-1324. doi: 10.1093/neuonc/noae045.
2
Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.1型神经纤维瘤病患者的视路胶质瘤:44例患者的随访
J AAPOS. 2010 Apr;14(2):155-8. doi: 10.1016/j.jaapos.2009.11.020.
3
Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients.1型神经纤维瘤病与视路胶质瘤:54例患者的随访
Ophthalmology. 2004 Mar;111(3):568-77. doi: 10.1016/j.ophtha.2003.06.008.
4
Neurofibromatosis Type 1-Associated Optic Pathway Glioma in Children: A Follow-Up of 10 Years or More.儿童 1 型神经纤维瘤病相关视神经胶质瘤:10 年以上的随访。
Am J Ophthalmol. 2021 Jan;221:91-96. doi: 10.1016/j.ajo.2020.03.053. Epub 2020 Apr 10.
5
Pretreatment Endocrine Disorders Due to Optic Pathway Gliomas in Pediatric Neurofibromatosis Type 1: Multicenter Study.儿童 1 型神经纤维瘤病伴视路胶质瘤的预处理内分泌紊乱:多中心研究。
J Clin Endocrinol Metab. 2020 Jun 1;105(6). doi: 10.1210/clinem/dgaa138.
6
Neurofibromatosis type 1 and sporadic optic gliomas.1型神经纤维瘤病与散发性视神经胶质瘤。
Arch Dis Child. 2002 Jul;87(1):65-70. doi: 10.1136/adc.87.1.65.
7
Clinical Presentation and Outcome of Patients With Optic Pathway Glioma.视神经胶质瘤患者的临床表现和预后。
Pediatr Neurol. 2017 Oct;75:55-60. doi: 10.1016/j.pediatrneurol.2017.06.019. Epub 2017 Jul 6.
8
Visual acuity of children treated with chemotherapy for optic pathway gliomas.化疗治疗视路胶质瘤儿童的视力。
Pediatr Blood Cancer. 2014 Feb;61(2):223-7. doi: 10.1002/pbc.24726. Epub 2013 Aug 19.
9
Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1.序列 MRI 为神经纤维瘤病 1 患者视神经胶质瘤的自然病程提供了新的见解。
Orphanet J Rare Dis. 2018 Apr 23;13(1):62. doi: 10.1186/s13023-018-0811-9.
10
Optic pathway gliomas in children: Clinical characteristics, treatment, and outcome of 95 patients in a single center over a 31-year period. Can we avoid radiotherapy?儿童视神经胶质瘤:31 年间单中心 95 例患者的临床特征、治疗和结局。我们能否避免放疗?
Pediatr Blood Cancer. 2024 Dec;71(12):e31337. doi: 10.1002/pbc.31337. Epub 2024 Sep 29.

引用本文的文献

1
MRI-based, three-dimensionally assessed tumor burden and growth velocity to predict visual acuity deterioration in optic pathway glioma - results of a retrospective longitudinal analysis.基于磁共振成像(MRI)的三维评估肿瘤负荷和生长速度以预测视路胶质瘤的视力恶化——一项回顾性纵向分析的结果
Childs Nerv Syst. 2025 Jul 11;41(1):230. doi: 10.1007/s00381-025-06890-6.
2
A Retrospective, Nationwide, Multicenter Study on Diagnosis and Treatment Outcome of Pediatric Optic Pathway/Hypothalamic Gliomas Including Analysis of Risk Factors for Progression After Systemic Anticancer Therapy.一项关于儿童视神经通路/下丘脑胶质瘤诊断与治疗结果的回顾性、全国性、多中心研究,包括全身抗癌治疗后进展危险因素分析。
Cancers (Basel). 2025 Feb 20;17(5):716. doi: 10.3390/cancers17050716.
3
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial.在FIREFLY-1试验中,复发/难治性视路胶质瘤患儿对II型RAF抑制剂托法替尼的影像学和视觉反应。
Neuro Oncol. 2025 Jun 21;27(5):1341-1355. doi: 10.1093/neuonc/noae274.
4
Paediatric low-grade glioma: the role of classical pathology in integrated diagnostic practice.小儿低度神经胶质瘤:经典病理学在综合诊断实践中的作用。
Childs Nerv Syst. 2024 Oct;40(10):3189-3207. doi: 10.1007/s00381-024-06591-6. Epub 2024 Sep 18.
5
Surgical options of chiasmatic hypothalamic glioma-a relevant part of therapy in an interdisciplinary approach for tumor control.视交叉下丘脑胶质瘤的手术选择 - 肿瘤控制的多学科治疗中的一个相关部分。
Childs Nerv Syst. 2024 Oct;40(10):3065-3074. doi: 10.1007/s00381-024-06498-2. Epub 2024 Jun 25.
6
Optic pathway gliomas: Long-term outcomes and challenges.视路胶质瘤:长期预后及挑战
Neuro Oncol. 2024 Jul 5;26(7):1325-1326. doi: 10.1093/neuonc/noae079.

本文引用的文献

1
Predictive factors of long-term follow-up attendance in very long-term childhood cancer survivors.极长期儿童癌症幸存者长期随访参与情况的预测因素
Cancer. 2023 Nov 1;129(21):3476-3489. doi: 10.1002/cncr.34944. Epub 2023 Jul 11.
2
Optic pathway glioma and endocrine disorders in patients with and without NF1.患有和未患有1型神经纤维瘤病(NF1)患者的视路胶质瘤与内分泌紊乱
Pediatr Res. 2023 Jan;93(1):233-241. doi: 10.1038/s41390-022-02098-5. Epub 2022 May 10.
3
The role of imaging features and resection status in the survival outcome of sporadic optic pathway glioma children receiving different adjuvant treatments.影像学特征和切除状态对接受不同辅助治疗的散发性视神经胶质瘤患儿生存结果的作用。
Neurosurg Rev. 2022 Jun;45(3):2277-2287. doi: 10.1007/s10143-022-01743-1. Epub 2022 Feb 1.
4
Drugs Associated With Ischemic Stroke: A Review for Clinicians.与缺血性脑卒中相关的药物:临床医生的综述。
Stroke. 2021 Oct;52(10):e646-e659. doi: 10.1161/STROKEAHA.120.033272. Epub 2021 Aug 18.
5
Phase I study of vinblastine in combination with nilotinib in children, adolescents, and young adults with refractory or recurrent low-grade glioma.长春碱联合尼洛替尼治疗难治性或复发性低级别胶质瘤儿童、青少年及青年成人的I期研究。
Neurooncol Adv. 2020 Jun 9;2(1):vdaa075. doi: 10.1093/noajnl/vdaa075. eCollection 2020 Jan-Dec.
6
Pretreatment Endocrine Disorders Due to Optic Pathway Gliomas in Pediatric Neurofibromatosis Type 1: Multicenter Study.儿童 1 型神经纤维瘤病伴视路胶质瘤的预处理内分泌紊乱:多中心研究。
J Clin Endocrinol Metab. 2020 Jun 1;105(6). doi: 10.1210/clinem/dgaa138.
7
Current treatment of optic nerve gliomas.视神经胶质瘤的治疗现状。
Curr Opin Ophthalmol. 2019 Sep;30(5):356-363. doi: 10.1097/ICU.0000000000000587.
8
Long-term visual acuity in patients with optic pathway glioma treated during childhood with up-front BB-SFOP chemotherapy-Analysis of a French pediatric historical cohort.儿童期接受 upfront BB-SFOP 化疗治疗的视神经胶质瘤患者的长期视力-法国儿科历史队列分析。
PLoS One. 2019 Mar 8;14(3):e0212107. doi: 10.1371/journal.pone.0212107. eCollection 2019.
9
Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations.小儿脑胶质瘤的分子谱分析和靶向治疗:综述与共识建议。
Neuro Oncol. 2019 Aug 5;21(8):968-980. doi: 10.1093/neuonc/noz022.
10
A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - A final report.一项欧洲随机对照试验,在针对儿童(≤16岁)低级别胶质瘤的18个月治疗方案中,在标准长春新碱和卡铂诱导治疗基础上加用依托泊苷——最终报告。
Eur J Cancer. 2017 Aug;81:206-225. doi: 10.1016/j.ejca.2017.04.019. Epub 2017 Jun 22.

儿童视神经胶质瘤治疗后非常长期的结果:一项纵向队列研究。

Very long-term outcomes of pediatric patients treated for optic pathway gliomas: A longitudinal cohort study.

机构信息

Department of Children and Adolescents Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France.

Radiation Epidemiology Group, INSERM Unit 1018, Villejuif, France.

出版信息

Neuro Oncol. 2024 Jul 5;26(7):1310-1324. doi: 10.1093/neuonc/noae045.

DOI:10.1093/neuonc/noae045
PMID:38465768
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11226872/
Abstract

BACKGROUND

Optic pathway gliomas (OPGs) represent 5% of childhood brain tumors. Successive relapses lead to multiple treatments exposing to late complications.

METHODS

We included patients treated at Gustave Roussy (GR) between January 1980 and December 2015 for OPG, before 18 years old and alive at 5 years from diagnosis. Mortality and physical health conditions data were extracted from medical data files and updated, thanks to the GR long-term follow-up program and French national mortality registry for patients included in the French Childhood Cancer Survivor Study.

RESULTS

We included 182 5-year OPG-childhood survivors in the analysis (sex ratio M/F 0.8, 35% with neurofibromatosis type 1 [NF1]). With a median follow-up of 17.2 years (range = 5-41), we registered 82 relapses, 9 second malignancies, and 15 deaths as first events after 5 years, resulting in 20-year conditional overall survival (C-OS) and late events-free survival of 79.9% (95% confidence interval [CI] = 71-86) and 43.5% (95% CI = 36-51), respectively. Radiotherapy exposure in NF1 patients (hazard ratio [HR] = 6, 95% CI = 1.7-21.2) and hypothalamic involvement (HR = 3.2, 95% CI = 1.4-7.3) were significantly associated with C-OS in multivariable analyses. Ninety-five percent of 5-year OPG survivors suffered from any health condition, especially visual acuity "<1/10" (n = 109), pituitary deficiency (n = 106), and neurocognitive impairment (n = 89). NF1 (HR 2.1) was associated with precocious puberty. With a median time post-diagnosis of 4.2 years, 33 cerebrovascular events were observed in 21 patients.

CONCLUSIONS

Late relapses, second malignancies, and cerebrovascular diseases are severe late events resulting in premature mortality. Morbidity is high and needs after-cancer care to improve quality of life. Risk factors could be considered to better stratify long-term follow-up.

摘要

背景

视神经胶质瘤(OPG)占儿童脑肿瘤的 5%。连续复发导致多次治疗,引发晚期并发症。

方法

我们纳入了 1980 年 1 月至 2015 年 12 月期间在 Gustave Roussy(GR)接受治疗的 OPG 患者,这些患者在 18 岁之前被诊断,并在诊断后 5 年时存活。通过 GR 长期随访计划和法国全国死亡率登记处,对患者的死亡率和身体健康状况数据进行了提取和更新,这些患者被纳入法国儿童癌症幸存者研究。

结果

我们纳入了 182 名 5 年 OPG 儿童幸存者进行分析(男女性别比为 0.8,35%伴有神经纤维瘤病 1 型 [NF1])。中位随访时间为 17.2 年(范围 5-41 年),我们记录了 82 例复发、9 例第二恶性肿瘤和 15 例 5 年后首次发生的死亡事件,导致 20 年条件总生存(C-OS)和晚期无事件生存分别为 79.9%(95%CI 71-86)和 43.5%(95%CI 36-51)。NF1 患者的放疗暴露(风险比[HR] = 6,95%CI = 1.7-21.2)和下丘脑受累(HR = 3.2,95%CI = 1.4-7.3)在多变量分析中与 C-OS 显著相关。95%的 5 年 OPG 幸存者患有任何健康状况,特别是视力"<1/10"(n=109)、垂体功能减退(n=106)和神经认知障碍(n=89)。NF1(HR 2.1)与性早熟有关。中位诊断后时间为 4.2 年,21 名患者中有 33 例发生脑血管事件。

结论

晚期复发、第二恶性肿瘤和脑血管疾病是导致过早死亡的严重晚期事件。发病率高,需要癌症后护理以提高生活质量。可以考虑风险因素来更好地分层长期随访。